495
Views
16
CrossRef citations to date
0
Altmetric
Review

Management of severe complications in Behçet’s disease with TNF inhibitors

, , , , &
Pages 853-859 | Received 24 Feb 2017, Accepted 05 May 2017, Published online: 19 May 2017

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Mitsuhiro Akiyama, Yuko Kaneko & Tsutomu Takeuchi. (2020) Does microbiome contribute to HLA-B52-positive Takayasu arteritis?. Modern Rheumatology 30:1, pages 213-217.
Read now

Articles from other publishers (15)

João Araújo Correia, Jorge Crespo, Glória Alves, Fernando Salvador, João Matos-Costa, José Delgado Alves, Jorge Fortuna, Isabel Almeida, Ana Campar, Mariana Brandão, Raquel Faria, Daniela Marado, Susana Oliveira, Lelita Santos, Fátima Silva, Carlos Vasconcelos, Milene Fernandes & António Marinho. (2023) Biologic therapy in large and small vessels vasculitis, and Behçet’s disease: Evidence- and practice-based guidance. Autoimmunity Reviews 22:8, pages 103362.
Crossref
Zhimian Wang, Xiaoou Wang, Weiwei Liu, Yuhua Wang, Jinjing Liu, Li Zhang, Shangzhu Zhang, Xinping Tian, Yan Zhao & Wenjie Zheng. (2023) Baricitinib for the treatment of refractory vascular Behçet's disease. Clinical Immunology 250, pages 109298.
Crossref
Qinyun Xia, Chujun Lyu, Fang Li, Binbin Pang, Xiaoyu Guo, He Ren, Yiqiao Xing & Zhen Chen. (2022) Candidate Drugs Screening for Behcet’s Disease Based on Bioinformatics Analysis and Mouse Experiments. Frontiers in Immunology 13.
Crossref
Yutaro Soejima, Yohei Kirino, Mitsuhiro Takeno, Michiko Kurosawa, Masaki Takeuchi, Ryusuke Yoshimi, Yumiko Sugiyama, Shigeru Ohno, Yukiko Asami, Akiko Sekiguchi, Toshihisa Igarashi, Shohei Nagaoka, Yoshiaki Ishigatsubo, Hideaki Nakajima & Nobuhisa Mizuki. (2021) Changes in the proportion of clinical clusters contribute to the phenotypic evolution of Behçet’s disease in Japan. Arthritis Research & Therapy 23:1.
Crossref
Demet Yalçın Kehribar & Metin Ozgen. (2020) Infliximab treatment in refractory vascular Behcet’s disease: A single-center experience. Vascular 28:6, pages 829-833.
Crossref
David Saadoun. (2020) Behçet's disease: The French recommendations. La Revue de Médecine Interne 41:7, pages 437-439.
Crossref
Chen-Hong Lin, Dan Luo, Hai-Fen Ma, Yan Shen, Jun Zou & Jian-Long Guan. (2020) Clinical characteristics and factors influencing the prognosis of Behçet’s disease complicated with vascular involvement. Vasa 49:4, pages 309-318.
Crossref
Aysun Aksoy, Ayten Yazici, Ahmet Omma, Ayse Cefle, Fatos Onen, Unal Tasdemir, Tulin Ergun, Haner Direskeneli & Fatma Alibaz‐Oner. (2020) Efficacy of TNFα inhibitors for refractory vascular Behçet's disease: A multicenter observational study of 27 patients and a review of the literature. International Journal of Rheumatic Diseases 23:2, pages 256-261.
Crossref
Yuki Nanke & Shigeru Kotake. 2020. Different Aspects of Behçet's Disease. Different Aspects of Behçet's Disease.
Fatma Alibaz-Oner & Haner Direskeneli. (2019) Management of vascular Behçet's disease. International Journal of Rheumatic Diseases 22, pages 105-108.
Crossref
David B. Sachar. (2018) Small Bowel Lesions Mimicking Crohn’s Disease. Current Gastroenterology Reports 20:9.
Crossref
Meriam Messedi, Manel Naifar, Sahar Grayaa, Faten Frikha, Mariem Messoued, Mohamed Marouene Sethom, Moncef Feki, Naziha Kaabach, Zouheir Bahloul, Kamel Jamoussi & Fatma Ayedi. (2018) Plasma Saturated and Monounsaturated Fatty Acids in Behçet’s Disease. The Open Rheumatology Journal 12:1, pages 139-151.
Crossref
Fatma Alibaz-Oner, Amr H. Sawalha & Haner Direskeneli. (2018) Management of Behçet's disease. Current Opinion in Rheumatology 30:3, pages 238-242.
Crossref
Loic Guillevin, Chetan Mukhtyar, Christian Pagnoux & Max Yates. (2018) Conventional and biological immunosuppressants in vasculitis. Best Practice & Research Clinical Rheumatology 32:1, pages 94-111.
Crossref
Selen Ozyurt, Petros Sfikakis, Aksel Siva & Cris S Constantinescu. (2018) Neuro-Behçet’s Disease – Clinical Features, Diagnosis and Differential Diagnosis. European Neurological Review 13:2, pages 93.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.